Fundamentals Hub
ANVS Annovis Bio, Inc.
ANVS financial statements, revenue, balance sheet, cash flow, and SEC filings
▼ Company Profile
▼ Key Metrics (TTM)
As of Jun 30, 2026Sources and calculation details
Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.
Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.
| Metric | FY2025 📄 | FY2024 📄 | FY2023 📄 |
|---|---|---|---|
| Income Statement | |||
| REVENUE | |||
| Revenue | $0 | $0 | $0 |
| OPERATING EXPENSES | |||
| R&D Expense | $25.22M | $20.00M | $38.79M |
| SG&A Expense | $4.48M | $6.70M | $6.24M |
| Operating Income | $-29.70M | $-26.69M | $-45.04M |
| NON-OPERATING INCOME / EXPENSE | |||
| Interest Income | $699.06K | $331.85K | $667.90K |
| Other Income/Expense | $841.06K | $2.10M | $-11.17M |
| Pretax Income | - | - | $-56.20M |
| Income Tax | $0 | - | - |
| Net Income | $-28.85M | $-24.59M | $-56.20M |
| PER SHARE & SUPPLEMENTAL | |||
| Diluted EPS | $-1.40 | $-2.31 | $-6.23 |
| Diluted Shares | 20.55M | 12.24M | 9.02M |
| Balance Sheet | |||
| ASSETS | |||
| Cash & Equivalents | $19.53M | $10.55M | $5.75M |
| Current Assets | - | - | $10.21M |
| Noncurrent Assets | - | - | $0 |
| Total Assets | $21.08M | $13.93M | $10.21M |
| LIABILITIES | |||
| Accounts Payable | $2.59M | $2.31M | $1.29M |
| Current Liabilities | $3.64M | $3.88M | $4.28M |
| Noncurrent Liabilities | $595.00K | $737.00K | $13.68M |
| Total Liabilities | $4.23M | $4.62M | $17.96M |
| EQUITY | |||
| Common Stock | $2.72K | $1.41K | $1.05K |
| Additional Paid-in Capital | $180.55M | $144.16M | $102.51M |
| Retained Earnings | $-163.70M | $-134.85M | $-110.26M |
| Total Equity | $16.85M | $9.31M | $-7.75M |
| Total Liabilities & Equity | $21.08M | $13.93M | $10.21M |
| SUPPLEMENTAL | |||
| Shares Outstanding | 27.20M | 14.14M | 10.52M |
| Check: A − (L + E + Temp. Equity) | - | - | - |
| Cash Flow Statement | |||
| Cash from Operations | $-25.62M | $-21.89M | $-39.97M |
| Capital Expenditures | - | - | - |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $34.60M | $26.69M | $17.34M |
| Free Cash Flow | - | - | - |
| Beginning Cash (CFS) | $10.55M | $5.75M | $28.38M |
| Net Change in Cash | $8.98M | $4.80M | $-22.62M |
| Effect of FX on Cash | - | - | - |
| Calculated Ending Cash | $19.53M | $10.55M | $5.75M |
| Cash per BS | $19.53M | $10.55M | $5.75M |
| Cash scope difference (CFS − BS) | - | - | - |
| Cash per CFS | $19.53M | $10.55M | $5.75M |
Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.
Create Free Account Log InQuarterly data and charts require a free account
Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.
▼ Frequently Asked Questions
What is Annovis Bio, Inc.'s annual revenue?
Annovis Bio, Inc. reported $0 in revenue for trailing twelve months (ending June 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.
Is Annovis Bio, Inc. profitable?
No. Annovis Bio, Inc. reported $-49.52M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.